Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14626 - 14650 of 15163 in total
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Investigational
TAK-428 is a drug for treating diabetic neuropathy. It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Investigational
Matched Description: … based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and
Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the hydrazine chemical class. It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.
Withdrawn
Matched Description: … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging …
GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).
Investigational
Matched Description: … investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and
Experimental
Matched Iupac: … phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-2-hydroxy-3-methylbutanamido]propanamido}-2-fluorobutanoic acid
Investigational
Matched Iupac: … azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-yl]oxy}oxane-2-carboxylic acid
Experimental
123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and
Displaying drugs 14626 - 14650 of 15163 in total